The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Courtney E. Bakan, Anjali Mishra, +14

Blood

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, +166

The Lancet

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, +81

The Lancet Oncology

Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat +4

Non-Hodgkin's Lymphomas

Andrew D. Zelenetz, John C. Krauss, Pierluigi Porcu, +1

Journal of the National Comprehensive Cancer Network

Primary ImmunodeficiencyLymphoid NeoplasiaLymphocyte DevelopmentMediastinum NhlsImmunology +10

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer, +64

Journal of Clinical Oncology

Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

Patrick J. Stiff, Joseph M. Unger, James R. Cook, +17

New England Journal of Medicine

Non-Hodgkin’s Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, +27

Journal of the National Comprehensive Cancer Network

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, +17

Blood

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Ian W. Flinn, Susan O’Brien, Brad S. Kahl, +13

Blood

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Guido Marcucci, John C. Byrd, Guowei Dai, +17

Blood